Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALTEC
2023-508212-38-00Phase 2Authorised
- Sponsor
- North Estonia Medical Centre
- Start
- Mar 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of talquetamab and teclistamab in multiple myeloma (MM), sponsored by North Estonia Medical Centre. Primary endpoint: MRD negativity after talquetamab and teclistamab consolidation. Planned start Mar 2024; status: authorised.
02
Drugs
talquetamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-508212-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508212-38-00.